Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Oral Biologics & Biosimilars Market Size, Value And Growth Trajectory Through 2030
The oral biologics & biosimilars market has experienced substantial expansion in recent years. This market is set to increase from $9.37 billion in 2025 to $11.28 billion in 2026, registering a compound annual growth rate (CAGR) of 20.3%. The drivers behind its historical growth include the limited availability of oral biologics, the high cost of biologic therapies, a reliance on injectable formulations, the rising prevalence of chronic diseases, and the expanding networks of hospitals and retail pharmacies.
The oral biologics & biosimilars market size is anticipated to experience substantial growth in the upcoming years. It is projected to reach $24.69 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 21.6%. This expected expansion is driven by factors such as the progress in biosimilar and combination therapy development, the broadening of oral biologics pipelines, an increasing patient preference for oral medications, the rising use of digital adherence tools, and supportive government policies and reimbursement systems. Key trends in the forecast period include the growing acceptance of oral biologics and biosimilars for chronic diseases, an increase in targeted therapies for conditions like diabetes, arthritis, and cancer, the accelerated creation of monoclonal antibody-based oral treatments, the expansion of distribution channels through hospitals, retail outlets, and online pharmacies, and an emphasis on patient adherence and personalized treatment strategies.
Get A Free Sample Report With In-Depth Market Insights:
Oral Biologics & Biosimilars Market Industry Drivers: What’s Behind The Revenue Growth?
The increasing incidence of chronic illnesses is anticipated to fuel the expansion of the oral biologics and biosimilar market in the future. These enduring health conditions, which often advance gradually, include conditions like diabetes, cardiovascular diseases, and respiratory disorders. A significant factor contributing to this increase in chronic diseases is sedentary lifestyles, where extended periods of physical inactivity elevate the risk of obesity, heart disease, type 2 diabetes, and specific cancers. Oral biologics and biosimilars facilitate this trend by offering patients managing chronic conditions more accessible, economical, and convenient treatment alternatives. For example, data from January 2023, provided by the Centers for Disease Control and Prevention (CDC), a US-based federal agency, indicated that in 2023, 76.4% of U.S. adults (roughly 194 million individuals) reported having at least one chronic condition. The prevalence rates were 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Consequently, the growing prevalence of chronic diseases is a primary impetus for the expansion of the oral biologics and biosimilar market.
Oral Biologics & Biosimilars Market Segments: Where Is Growth Concentrated?
The oral biologics & biosimilars market covered in this report is segmented –
1) By Therapy: Lymphocyte Modulators, Immunostimulants, GPCR Modulators, Other Therapies
2) By Disease: Diabetes, Arthritis and Crohn’s Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases
3) By Molecule Type: Vaccines, Proteins and Peptides, Other Molecule Types
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Lymphocyte Modulators: T-Cell Modulators, B-Cell Modulators, Sphingosine-1-Phosphate Receptor Modulators
2) By Immunostimulants: Cytokines, Immune Checkpoint Inhibitors, Adjuvants
3) By GPCR Modulators: Agonists, Antagonists, Biased Ligands
4) By Other Therapies: Cell-Based Therapies, Gene Therapies, Combination Therapies
#Oral Biologics & Biosimilars Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies in the oral biologics & biosimilars market are concentrating on creating innovative solutions, such as customized smart capsule development services, to enhance the oral delivery of biologics, improve their bioavailability, and offer a patient-friendly administration method compared to traditional injectable formulations. These smart capsules incorporate advanced coatings, controlled-release matrices, or protective excipients to shield biologics from degradation within the gastrointestinal tract and optimize absorption in targeted intestinal regions, presenting a non-invasive alternative to injections and boosting patient adherence. For example, in December 2024, Lonza Group AG, a Switzerland-based contract development and manufacturing organization (CDMO), introduced a tailored service for smart capsule development, specifically to aid oral biologics development. This service provides customized formulation design, selection of protective excipients, and capsule engineering to ensure the stability and targeted release of biologics. It operates by improving the oral bioavailability of sensitive biomolecules while preserving their therapeutic efficacy. Its distinguishing characteristics include comprehensive support from the initial concept to preclinical testing, compatibility with various biologic modalities (proteins, peptides, nucleic acids), and scalable manufacturing solutions. Applications extend to the oral delivery of monoclonal antibodies, therapeutic peptides, and vaccines. The advantages include greater patient convenience, reduced dependence on injections, improved compliance, and expedited development timelines for oral biologic therapies.
Oral Biologics & Biosimilars Market Key Participants And Competitive Landscape
Major companies operating in the oral biologics & biosimilars market are Merck & Co. Inc., GlaxoSmithKline, Novo Nordisk, BiosanaPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Pfizer Inc., Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Altis Biologics, Cipla Medpro South Africa, Genzyme
View The Full Oral Biologics & Biosimilars Market Report:
Oral Biologics & Biosimilars Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the oral biologics and biosimilar drugs market in 2025. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model